Upadacitinib shows significant hair regrowth in severe alopecia areata trials

Clinical trials for the drug upadacitinib, originally developed to treat rheumatoid arthritis, have demonstrated significant success in treating severe alopecia areata. Results from the Phase 3 UP-AA clinical program, published in JAMA Dermatology, indicate that up to 23 percent of patients with severe hair loss achieved complete scalp hair regrowth within six months.

The studies involved nearly 1,400 participants across North America, Europe, and China. The medication, marketed by AbbVie under the brand name Rinvoq, is a Janus kinase (JAK) inhibitor that works by blocking immune system signals that trigger inflammatory responses. By suppressing these signals, the drug helps prevent the immune system from attacking hair follicles.

The trials included adults and adolescents who had lost at least 50 percent of their scalp hair. Participants were administered either 15 milligrams or 30 milligrams of the once-daily pill or a placebo. The findings represent one of the largest Phase 3 datasets for this treatment approach to date.